| 中文关键词: 小细胞肺癌 靶向治疗 研究进展 |
| 英文关键词:small cell lung cancer targeted therapy progress |
| 基金项目:国家自然科学基金（81672972） |
|
| 摘要点击次数: 2121 |
| 全文下载次数: 559 |
| 中文摘要: |
| 摘 要：小细胞肺癌（small cell lung cancer，SCLC）约占全部肺癌的15%~20%，其生物学行为表现为恶性程度高、侵袭性强、预后差。尽管初始治疗时对放、化疗敏感，但小细胞肺癌患者容易早期出现复发转移，因疾病进展后缺乏有效治疗手段，最终导致患者死亡。近十年，靶向治疗的发展给非小细胞肺癌的治疗策略带来了巨大改变。SCLC同样具有大量体细胞突变，针对不同靶点的分子靶向药物在SCLC患者治疗中亦进行了很多探索。虽然目前没有有效的靶向药物被批准用于治疗SCLC，一些新的靶向药物在临床研究中的疗效给SCLC的治疗带来了曙光。全文将对SCLC靶向治疗的研究现状及进展进行综述。 |
| 英文摘要: |
| Abstract：Small cell lung cancer(SCLC) accounts for 15%~20% of lung cancer cases and remains a very fatal disease because of its aggressive nature，usually with a dismal prognosis. Despite SCLC is sensitive to chemotherapy and radiotherapy initially，it is characterized by high relapse rates and a subsequent poor outcome due to limited options for effective treatment. Over the past decades，the development of targeted therapies based on genomic research has changed the therapeutic strategy for non-small cell lung cancer dramatically. SCLC has also been reported with large number of somatic mutations and several avenues have been explored to develop targeted therapies for this disease. Till now，no effective targeted therapies are available，however，some new drugs has shown promising effect in clinical trials. In this review，status and progress of targeted therapy in SCLC are reviewed. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
